{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4358","paramType":"Hazard Ratio (HR)","paramValue":"0.93","statisticalMethod":"Hazard Ratio"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"0.81","value":"0.77"},{"groupId":"OG001","lowerLimit":"0.71","upperLimit":"0.80","value":"0.76"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.53","upperLimit":"0.64","value":"0.59"},{"groupId":"OG001","lowerLimit":"0.49","upperLimit":"0.60","value":"0.55"}]}],"title":"2 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.40","upperLimit":"0.51","value":"0.46"},{"groupId":"OG001","lowerLimit":"0.35","upperLimit":"0.46","value":"0.41"}]}],"title":"3 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.31","upperLimit":"0.41","value":"0.36"},{"groupId":"OG001","lowerLimit":"0.28","upperLimit":"0.38","value":"0.33"}]}],"title":"4 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.21","upperLimit":"0.32","value":"0.26"},{"groupId":"OG001","lowerLimit":"0.20","upperLimit":"0.30","value":"0.25"}]}],"title":"5 year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"description":"PFS rate is defined as the percentage of participants experiencing PFS at the defined time-points.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the specified time-point (up to 5 years)","title":"Progression Free Survival (PFS) Rate at Specific Time-points","type":"SECONDARY","unitOfMeasure":"Percent of participants"}